Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
about
Microglial Activation in the Pathogenesis of Huntington's Disease.CRISPR Editing Technology in Biological and Biomedical Investigation.Progress and Application of CRISPR/Cas Technology in Biological and Biomedical Investigation.Editing the genome of hiPSC with CRISPR/Cas9: disease models.A thiol probe for measuring unfolded protein load and proteostasis in cells.CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's DiseaseDrusen in patient-derived hiPSC-RPE models of macular dystrophies.Preclinical and clinical advances in transposon-based gene therapy.CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects.Neural stem cells and epilepsy: functional roles and disease-in-a-dish models.The prospects of CRISPR-based genome engineering in the treatment of neurodegenerative disorders.Reactive Neuroblastosis in Huntington's Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain.A homozygous loss-of-function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability.CRISPR therapeutic tools for complex genetic disorders and cancer (Review).Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation.The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington's disease patients
P2860
Q33809556-AF606362-5ECB-4ACD-913B-1689652EB5F4Q38688945-23722A5C-48B7-429C-92C9-F3354D60909DQ38700979-2FEAFB9E-6083-458E-AB19-2063D43E6B47Q38711908-7EA083A3-719D-4F32-83AB-B683D6F0AD2AQ41545945-0B1DDBBD-080B-4B28-8FEF-BFA70D23707FQ42289973-96B2ECBE-789D-4081-94B5-8BC1CF20A93AQ42514513-E3A9063C-B6FB-49E6-B2D1-8771D40C6A69Q45873802-E2A9B097-55D2-41EC-9CF7-EF4665F0ACD4Q47161696-EF39D4B1-5111-40FD-A8C8-CC169DB6AF9EQ48143836-06832B06-C0C6-483A-8893-AB74C8EDE49FQ49335959-291DBDDE-0F3F-45CB-8FAA-24CFACF4172FQ51758698-8BC685E6-7BF2-4E11-817C-D540BD7EC553Q54963859-36B6A059-892C-4840-A190-D2B06C4C3C01Q55383943-B5C651C7-9E88-465C-A83A-4AC8891F707AQ55711095-D45535AF-DE9C-44F8-B2ED-1D1CB1DEDF35Q58414022-381F94AC-D9C5-439C-B2E6-D6D15356DB14
P2860
Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@en
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@nl
type
label
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@en
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@nl
prefLabel
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@en
Reversal of Phenotypic Abnorma ...... nduced Pluripotent Stem Cells.
@nl
P2093
P2860
P921
P1433
P1476
Reversal of Phenotypic Abnorma ...... Induced Pluripotent Stem Cells
@en
P2093
Alvin Yu Jin Ng
Amin Ziaei
Bernice Sim
Carola Radulescu
Donovan Low
Florent Ginhoux
George J Augustine
Jolene Ooi
Kagistia Hana Utami
P2860
P304
P356
10.1016/J.STEMCR.2017.01.022
P577
2017-02-23T00:00:00Z